Literature DB >> 7052009

Response to phenelzine and amitriptyline in subtypes of outpatient depression.

E S Paykel, P R Rowan, R R Parker, A V Bhat.   

Abstract

Outpatients with depression and mixed anxiety-depression were treated for six weeks with phenelzine sulfate, amitriptyline hydrochloride, or placebo in a controlled trial. Both active drugs were superior to placebo and were closely comparable in efficacy. Interactions were examined between drug response and classifications based on three different usages of the term atypical depression: additional anxiety or phobic symptoms, atypical functional shift, and nonendogenous depression. Some additional related classifications were also included. There was a tendency for phenelzine to have stronger effects in patients with additional anxiety and without evidence of chronic characterological depression. However, interactions were relatively few. These findings suggest that the two classes of antidepressant affect similar clinical subgroups within the outpatient depressive spectrum, with only relatively weak differences.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7052009     DOI: 10.1001/archpsyc.1982.04290090035008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  8 in total

1.  The role of monoamine oxidase inhibitors in current psychiatric practice.

Authors:  Jess G Fiedorowicz; Karen L Swartz
Journal:  J Psychiatr Pract       Date:  2004-07       Impact factor: 1.325

2.  Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.

Authors:  R Uher; R H Perlis; N Henigsberg; A Zobel; M Rietschel; O Mors; J Hauser; M Z Dernovsek; D Souery; M Bajs; W Maier; K J Aitchison; A Farmer; P McGuffin
Journal:  Psychol Med       Date:  2011-09-20       Impact factor: 7.723

3.  Monoamine oxidase inhibitors in depression.

Authors:  P Rowan
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-15

4.  Strategies for the drug treatment of depression.

Authors:  A J Cooper; R V Magnus
Journal:  Can Med Assoc J       Date:  1984-02-15       Impact factor: 8.262

5.  Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.

Authors:  K White; J Razani; B Cadow; R Gelfand; R Palmer; G Simpson; R B Sloane
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  A cross-cultural comparative study of depressive symptoms in British and Turkish clinical samples.

Authors:  A Uluşahin; M Başoğlu; E S Paykel
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1994-02       Impact factor: 4.328

7.  Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl.

Authors:  V Glover; C J Pycock; M Sandler
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

Review 8.  Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors.

Authors:  Y Lecrubier
Journal:  Drug Saf       Date:  1994-04       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.